Board Meeting Outcomes

The Board of Directors meeting was held on November 4, 2026, from 6:30 PM to 9:20 PM at the registered office in Mumbai. The following matters were transacted:

1. Approval of Financial Results: Approved the Un-Audited Financial Results (Standalone and Consolidated) for the quarter and half year ended September 30, 2026, pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015.

2. Limited Review Report: Approved and took on record the Limited Review Report on the Un-Audited Financial Results issued by statutory auditors M/s DEVAM & Associates LLP, Chartered Accountants.

3. Statement of Deviation: Considered and took on record the Statement of deviation(s) or variation(s) pursuant to Regulation 32 of SEBI (LODR) Regulation, 2015, on use of proceeds from the objects stated in the Right Issue offer document.

4. Change in RTA: Approved change in Registrar & Transfer Agent (RTA) from Niche Technologies Pvt. Ltd to Skyline Financial Services Pvt. Ltd. Niche will continue to serve until completion of data transition, shifting of electronic connectivity, and receipt of necessary confirmations/approval from NSDL, CDSL and other authorities.

5. Fund Raising Approval: Approved proposal for raising funds through issuance of securities for an aggregate amount not exceeding ₹68,00,00,000 (₹68 Crores) to finance the proposed acquisition of 60% equity share capital of Meyonex Pharmaceuticals Limited (approved by board on October 7, 2026). The funds may be raised through preferential issue, rights issue, or any other permissible mode in one or more tranches. The Board authorized Executive Directors to appoint consultants and professionals to evaluate the most appropriate mode. Final decision on mode, structure, terms and conditions will be approved at a subsequent meeting.

Financial Results - Standalone (Amounts in ₹ Lacs)

Quarter Ended September 30, 2026:

  • Net Sales/Income from Operations: 15.80
  • Total Income: 15.80
  • Total Expenses: 67.87
  • Profit Before Tax: (52.07)
  • Total Tax Expenses: (0.66) [Deferred Tax: (0.66)]
  • Profit for the Period: (51.40)
  • EPS Basic: (0.01)
  • EPS Diluted: (0.01)

Half Year Ended September 30, 2026:

  • Net Sales/Income from Operations: 39.20
  • Total Income: 39.20
  • Total Expenses: 128.64
  • Profit Before Tax: (89.44)
  • Total Tax Expenses: (15.68) [Deferred Tax: (15.68)]
  • Profit for the Period: (73.75)
  • EPS Basic: (0.01)
  • EPS Diluted: (0.01)

Comparative Figures (Quarter Ended):

  • September 30, 2025: Net Profit of 60.40, EPS 0.02
  • June 30, 2026: Net Loss of (22.35), EPS (0.01)

Balance Sheet Highlights as of September 30, 2026:

  • Total Assets: ₹4,864.57 Lacs
  • Equity Share Capital: ₹3,836.01 Lacs
  • Other Equity: ₹332.56 Lacs
  • Short Term Borrowings: ₹414.18 Lacs
  • Trade Payables: ₹223.88 Lacs
  • Inventories: ₹908.27 Lacs (Trading Goods: ₹698.32 Lacs, Pharmaceutical Goods: ₹209.95 Lacs)
  • Trade Receivables: ₹698.43 Lacs
  • Cash and Cash Equivalents: ₹69.95 Lacs

Financial Results - Consolidated (Amounts in ₹ Lacs)

Quarter Ended September 30, 2026:

  • Net Sales/Income from Operations: 503.94
  • Other Income: 48.57
  • Total Income: 552.51
  • Total Expenses: 593.30
  • Profit Before Tax: (40.79)
  • Total Tax Expenses: (0.66) [Deferred Tax: (0.66)]
  • Profit for the Period: (40.12)
  • EPS Basic: (0.01)
  • EPS Diluted: (0.01)

Half Year Ended September 30, 2026:

  • Net Sales/Income from Operations: 568.39
  • Other Income: 60.19
  • Total Income: 628.58
  • Total Expenses: 700.40
  • Profit Before Tax: (71.82)
  • Total Tax Expenses: (15.68) [Deferred Tax: (15.68)]
  • Profit for the Period: (56.13)
  • EPS Basic: 0.0098
  • EPS Diluted: 0.0098

Consolidated Entities: Tavexia Lifecare Limited (Holding Company), Mayukh Trading Private Limited (Subsidiary), PavaPuri Export Private Limited (Subsidiary)

Limited Review Report

Statutory auditors DEVAM & Associates LLP issued a limited review report stating that nothing has come to their attention that causes them to believe that the financial results contain any material misstatement. The review was conducted in accordance with SRE 2410 issued by ICAI.

Change in RTA Details

Reason for change: Skyline Financial Services Pvt. Ltd has technologically advanced infrastructural framework to provide quick and quality services, presence, capacity to align with share registry activities and wider reach to the shareholders' base. Effective date will be intimated separately after carrying out necessary procedures and documentation.

Related Party Transactions (April 1, 2026 - September 30, 2026)

Total transactions of ₹44.38 Lacs, including:

  • Managing Director remuneration: ₹9.00 Lacs
  • Company Secretary remuneration: ₹1.50 Lacs
  • Director sitting fees: ₹1.08 Lacs
  • CFO remuneration: ₹1.56 Lacs
  • Subsidiary loan facility: ₹31.24 Lacs

Statement of Deviation for Right Issue Proceeds

Right issue raised ₹191,601,248.00 on July 7, 2025. No deviation/variation in use of funds raised. Funds utilized as per modified objects:

  • Working Capital Requirements: ₹220.00 Lacs (out of ₹470.00 Lacs allocated)
  • Business Expansion: ₹300.00 Lacs (out of ₹500.00 Lacs allocated)
  • Investment in Subsidiary: ₹1200.00 Lacs (out of ₹3500.00 Lacs allocated)
  • General corporate purposes: ₹116.16 Lacs (out of ₹400.00 Lacs allocated)
  • Issue-related expenses: ₹80.00 Lacs (out of ₹80.00 Lacs allocated)

Additional Information

The company operates in two business segments: Trading Business and Pharmaceutical Business Activities. The financial results are available on www.tavexia.com and www.bseindia.com.